

**EFFECTIVE DATE:** 05 | 20 | 2008

**POLICY LAST UPDATED:** 05 | 05 | 2021

## OVERVIEW

A variety of procedures are being developed to resurface articular cartilage defects. Autologous chondrocyte implantation (ACI) involves harvesting chondrocytes from healthy tissue, expanding the cells in vitro, and implanting the expanded cells into the chondral defect. Second- and third-generation techniques include combinations of autologous chondrocytes, scaffolds, and growth factors.

## MEDICAL CRITERIA

Not applicable

## PRIOR AUTHORIZATION

Prior Authorization is not required

## POLICY STATEMENT

### Medicare Advantage Plans

#### Allografting

Osteochondral allografting is covered as a technique to repair full-thickness chondral defects of the knee, large (area >1.5 cm<sup>2</sup>) or cystic (volume >3.0 cm<sup>3</sup>) osteochondral lesions of the talus or osteochondral lesions of the talus when autografting would be inadequate due to lesion size, depth or location.

Osteochondral allografting for all other joints is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

#### Autografting

Osteochondral autografting, using one or more cores of osteochondral tissue, is covered for full thickness cartilage defects of the knee or osteochondral lesions of the talus.

Osteochondral autografting for all other joints is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

#### Autologous minced or particulated cartilage

Treatment of focal articular cartilage lesions with autologous minced or particulated cartilage is considered not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

#### Commercial Products

Osteochondral allografting may be considered **medically necessary** as a technique to repair full-thickness chondral defects of the knee, large (area >1.5 cm<sup>2</sup>) or cystic (volume >3.0 cm<sup>3</sup>) osteochondral lesions of the talus or osteochondral lesions of the talus when autografting would be inadequate due to lesion size, depth or location.

Osteochondral allografting for all other joints is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

## **Autografting**

Osteochondral autografting, using one or more cores of osteochondral tissue, may be considered medically necessary for full thickness cartilage defects of the knee or osteochondral lesions of the talus.

Osteochondral autografting for all other joints is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

## **Autologous minced or particulated cartilage**

Treatment of focal articular cartilage lesions with autologous minced or particulated cartilage is considered not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

## **COVERAGE**

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable surgery benefits/coverage.

## **BACKGROUND**

For individuals who have focal articular cartilage lesion(s) of the weight-bearing surface of the femoral condyles, trochlea, or patella who receive ACI, the evidence includes systematic reviews, randomized controlled trials, and prospective observational studies. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, and quality of life. There is a large body of evidence on ACI for the treatment of focal articular cartilage lesions of the knee. For large lesions, ACI results in better outcomes than microfracture, particularly in the long term. In addition, there is a limit to the size of lesions that can be treated with osteochondral autograft transfer, due to a limit on the number of osteochondral cores that can be safely harvested. As a result, ACI has become the established treatment for large articular cartilage lesions in the knee. In 2017, first-generation ACI with a collagen cover was phased out and replaced with an ACI preparation that seeds the chondrocytes onto a bioresorbable collagen sponge. Although the implantation procedure for this second-generation ACI is less technically demanding, studies to date have not shown improved outcomes compared with first-generation ACI. Some evidence has suggested an increase in hypertrophy (overgrowth) of the new implant that may exceed that of the collagen membrane covered implant. Long-term studies with a larger number of patients will be needed to determine whether this hypertrophy impacts graft survival. Based on mid-term outcomes that approximate those of first-generation ACI and the lack of alternatives, second-generation ACI may be considered an option for large disabling full-thickness cartilage lesions of the knee. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

It is typically done on individuals with the following:

- Adolescent patients should be skeletally mature with documented closure of growth plates (eg,  $\geq 15$  years). Adult patients should be too young to be considered an appropriate candidate for total knee arthroplasty or other reconstructive knee surgery (eg,  $< 55$  years)
- Focal, full-thickness (grade III or IV) unipolar lesions of the weight-bearing surface of the femoral condyles, trochlea, or patella at least 1.5 cm<sup>2</sup> in size
- Documented minimal to absent degenerative changes in the surrounding articular cartilage (Outerbridge grade II or less), and normal-appearing hyaline cartilage surrounding the border of the defect
- Normal knee biomechanics or alignment and stability achieved concurrently with autologous chondrocyte implantation.

For individuals who have focal articular cartilage lesions of joints other than the knee who receive ACI, the evidence includes systematic reviews of case series. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, and quality of life. The greatest amount of literature is for ACI of the talus. Comparative trials are needed to determine whether ACI improves outcomes for lesions in joints other than the knee. The evidence is insufficient to determine the effects of the technology on health outcomes.

Clinical input has been requested on multiple occasions, obtained most recently in 2015, on the use of ACI in the patella. Prior input supported use for localized chondral defects when other treatments have not been successful. The most recent input was generally supportive of the use of ACI for large patellar lesions, although the degree of support varied. Reviewers indicated that outcomes were improved when realignment procedures are performed concurrently with ACI of the patella and that success rates are lower when using ACI after a prior microfracture. Most reviewers recommended that a prior surgical procedure not be required for lesions greater than 4 cm<sup>2</sup>

## **CODING**

### **Medicare Advantage Plans and Commercial Products:**

**The following surgery codes are considered medically necessary when filed with an approved diagnosis.**

27415 Osteochondral allograft, knee, open

27416 Osteochondral autograft(s), knee, open (eg, mosaicplasty) (includes harvesting of autograft[s])

29866 Arthroscopy, knee, surgical; osteochondral autograft(s) (eg, mosaicplasty) includes harvesting of the autograft[

29867 Arthroscopy, knee, surgical; osteochondral allograft (eg, mosaicplasty)

**The following code is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products:**

28446 Open osteochondral autograft, talus (includes obtaining graft[s])

### **Approved diagnosis**

M17.0-M17.12	Osteoarthritis of knee primary code range
M17.4-M17.5	Osteoarthritis of knee secondary code range
M17.9	Osteoarthritis of knee unspecified code range
M12.561-M12.569	Traumatic arthropathy, knee code range
M23.90-M23.92	Unspecified, internal derangement of knee code range
M23.8x1-M23.8x9	Other internal derangement of knee code range
M25.861-M25.869	Other specified joint disorder, knee code range
M93.261-M93.269	Osteochondritis dissecans knee code range
M89.8x6	Other specified disorder of bone, lower leg
M94.8x6	Other specified disorder of cartilage, lower leg
S89.90-S89.92	Unspecified injury of lower leg code range
S99.811-S99.929	Other specified injures of ankle and foot code range

## **RELATED POLICIES**

None

## **PUBLISHED**

Provider Update, July 2021

Provider Update, July 2020

Provider Update December 2019

Provider Update, November 2018

Provider Update January 2017

## **REFERENCES:**

1. Riboh JC, Cvetanovich GL, Cole BJ, et al. Comparative efficacy of cartilage repair procedures in the knee: a network meta-analysis. *Knee Surg Sports Traumatol Arthrosc.* Dec 2017;25(12):3786-3799. PMID 27605128

2. Devitt BM, Bell SW, Webster KE, et al. Surgical treatments of cartilage defects of the knee: Systematic review of randomised controlled trials. *Knee*. Jun 2017;24(3):508-517. PMID 28189406
3. Mundi R, Bedi A, Chow L, et al. Cartilage restoration of the knee: a systematic review and meta-analysis of level 1 studies. *Am J Sports Med*. Jul 2016;44(7):1888-1895. PMID 26138733
4. Mistry H, Connock M, Pink J, et al. Autologous chondrocyte implantation in the knee: systematic review and economic evaluation. *Health Technol Assess*. Feb 2017;21(6):1-294. PMID 28244303
5. Harris JD, Siston RA, Pan X, et al. Autologous chondrocyte implantation: a systematic review. *J Bone Joint Surg Am*. Sep 15 2010;92(12):2220-2233. PMID 20844166
6. Bartlett W, Skinner JA, Gooding CR, et al. Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: a prospective, randomised study. *J Bone Joint Surg Br*. May 2005;87(5):640-645. PMID 15855365
7. Saris D, Price A, Widuchowski W, et al. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: two-year follow-up of a prospective randomized trial. *Am J Sports Med*. Jun 2014;42(6):1384-1394. PMID 24714783
8. Basad E, Ishaque B, Bachmann G, et al. Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study. *Knee Surg Sports Traumatol Arthrosc*. Apr 2010;18(4):519-527. PMID 20062969
9. Basad E, Wissing FR, Fehrenbach P, et al. Matrix-induced autologous chondrocyte implantation (MACI) in the knee: clinical outcomes and challenges. *Knee Surg Sports Traumatol Arthrosc*. Dec 2015;23(12):3729-3735. PMID 25218576
10. Schuette HB, Kraeutler MJ, McCarty EC. Matrix-assisted autologous chondrocyte transplantation in the knee: a systematic review of mid- to long-term clinical outcomes. *Orthop J Sports Med*. Jun 2017;5(6):2325967117709250. PMID 28620621
11. Meyerkort D, Ebert JR, Ackland TR, et al. Matrix-induced autologous chondrocyte implantation (MACI) for chondral defects in the patellofemoral joint. *Knee Surg Sports Traumatol Arthrosc*. Oct 2014;22(10):2522-2530. PMID 24817164
12. Zak L, Aldrian S, Wondrasch B, et al. Ability to return to sports 5 years after matrix-associated autologous chondrocyte transplantation in an average population of active patients. *Am J Sports Med*. Dec 2012;40(12):2815-2821. PMID 23108635
13. Ebert JR, Fallon M, Wood DJ, et al. A prospective clinical and radiological evaluation at 5 years after arthroscopic matrix-induced autologous chondrocyte implantation. *Am J Sports Med*. Jan 2017;45(1):59-69. PMID 27587741
14. Ebert JR, Fallon M, Zheng MH, et al. A randomized trial comparing accelerated and traditional approaches to postoperative weightbearing rehabilitation after matrix-induced autologous chondrocyte implantation: findings at 5 years. *Am J Sports Med*. Jul 2012;40(7):1527-1537. PMID 22539536
15. Ebert JR, Smith A, Edwards PK, et al. Factors predictive of outcome 5 years after matrix-induced autologous chondrocyte implantation in the tibiofemoral joint. *Am J Sports Med*. Jun 2013;41(6):1245-1254. PMID 23618699
16. Ebert JR, Schneider A, Fallon M, et al. A comparison of 2-year outcomes in patients undergoing tibiofemoral or patellofemoral matrix-induced autologous chondrocyte implantation. *Am J Sports Med*. Sep 01 2017;363546517724761. PMID 28910133
17. Harris JD, Cavo M, Brophy R, et al. Biological knee reconstruction: a systematic review of combined meniscal allograft transplantation and cartilage repair or restoration. *Arthroscopy*. Oct 26 2011;27(3):409-418. PMID 21030203
18. Andriolo L, Merli G, Filardo G, et al. Failure of autologous chondrocyte implantation. *Sports Med Arthrosc Rev*. Mar 2017;25(1):10-18. PMID 28045868
19. Nawaz SZ, Bentley G, Briggs TW, et al. Autologous chondrocyte implantation in the knee: mid-term to long-term results. *J Bone Joint Surg Am*. May 21 2014;96(10):824-830. PMID 24875023
20. Minas T, Von Keudell A, Bryant T, et al. The John Insall Award: A minimum 10-year outcome study of autologous chondrocyte implantation. *Clin Orthop Relat Res*. Jan 2014;472(1):41-51. PMID 23979923
21. Minas T, Gomoll AH, Rosenberger R, et al. Increased failure rate of autologous chondrocyte implantation after previous treatment with marrow stimulation techniques. *Am J Sports Med*. May 2009;37(5):902-908. PMID 19261905

22. Ebert JR, Smith A, Fallon M, et al. Incidence, degree, and development of graft hypertrophy 24 months after matrix-induced autologous chondrocyte implantation: association with clinical outcomes. *Am J Sports Med.* Sep 2015;43(9):2208-2215. PMID 26163536
23. American Orthopaedic Foot and Ankle Society. Position Statement: The Use of Osteochondral Transplantation for the Treatment of Osteochondral Lesions of the Talus. [https://www.aofas.org/docs/default-source/research-and-policy/osteochondral-lesions-position-statement.pdf?sfvrsn=95e8c93b\\_2](https://www.aofas.org/docs/default-source/research-and-policy/osteochondral-lesions-position-statement.pdf?sfvrsn=95e8c93b_2). Accessed March 5, 2019.
24. American Academy of Orthopaedic Surgeons Diagnosis and Treatment of Osteochondritis Dissecans Work Group. The diagnosis and treatment of osteochondritis dissecans: Guideline and evidence report. 2010, December 4; [http://www.aaos.org/research/guidelines/OCD\\_guideline.pdf](http://www.aaos.org/research/guidelines/OCD_guideline.pdf). Accessed March 5, 2019.
25. Chambers HG, Shea KG, Anderson AF, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: the diagnosis and treatment of osteochondritis dissecans. *J Bone Joint Surg Am.* Jul 18 2012;94(14):1322-1324. PMID 22810404.
26. Trice ME, Bugbee WD, Greenwald AS, et al. Articular cartilage restoration: A review of currently available methods. 2010; [http://www.aaos.org/cc\\_files/aaosorg/research/committee/biologic/bi\\_se\\_2010.pdf](http://www.aaos.org/cc_files/aaosorg/research/committee/biologic/bi_se_2010.pdf). Accessed March 5, 2019.
27. National Institute for Health and Care Excellence. Mosaicplasty for symptomatic articular defects of the knee [IPG607]. <https://www.nice.org.uk/guidance/ipg607>. Accessed March 5, 2019.

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

